Chemistry:Sintilimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-PD-1 monoclonal antibody IBI308[1] |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]
It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]
Side effects
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]
Research
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
- ↑ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pdcd1-monoclonal-antibody-ibi308.
- ↑ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018. https://www.reuters.com/article/us-innovent-biologics-ipo/chinas-innovent-prices-hk-ipo-near-top-end-raises-421-million-sources-idUSKCN1MY06Q.
- ↑ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read". Asian Scientist Magazine. January 9, 2019. https://www.asianscientist.com/2019/01/pharma/innovent-eli-lilly-sintilimab-tyvyt-hodgkins-lymphoma/.
- ↑ "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology 13 (12): S1047. 2018. doi:10.1016/j.jtho.2018.10.018. https://www.jto.org/article/S1556-0864(18)33216-7/fulltext. Retrieved Dec 1, 2018.
- ↑ 5.0 5.1 "Sintilimab: First Global Approval". Drugs 79 (3): 341–346. February 2019. doi:10.1007/s40265-019-1066-z. PMID 30742278.
- ↑ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018. https://www.sec.gov/Archives/edgar/data/1648257/000164825718000075/c257-20181220ex991ad34d7.htm.
- ↑ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019. https://adisinsight.springer.com/drugs/800048000.
- ↑ 8.0 8.1 "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology 6 (1): e2–e3. January 2019. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711.
- ↑ "A first-in-human phase 1a trial of sintilimab (IBI308)". 2018 ASCO Annual Meeting. American Society of Clinical Oncology. 12 October 2019. https://meetinglibrary.asco.org/record/159464/abstract.
- ↑ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". PR NewsWire (Press release). Retrieved Feb 22, 2019.
 |  |
